This King of Prussia firm's Big Pharma deal with Merck goes against the tide

The King of Prussia biopharmaceutical company acquired the U.S. rights to a bacterial skin infection treatment from Merck.

Source: bizjournals.com Health Care:Biotechnology headlines - July 20, 2020 Category: Biotechnology Authors: John George Source Type: news